Home
About
Overview
Sharing Data
ORCID
Help
History (1)
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer.
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Cyclin-Dependent Kinase Inhibitor p16
Drug Resistance, Neoplasm
Female
Follow-Up Studies
Humans
Immunotherapy
Loss of Function Mutation
Lung Neoplasms
Male
Middle Aged
Prognosis
Retrospective Studies
Survival Rate
authors with profiles
Everett E. Vokes
Ralph R. Weichselbaum
Sean Pitroda
Christine Bestvina
Aditya Juloori
Steven Chmura
Philip P. Connell
Mark K. Ferguson
Jessica Donington
Angela Lager
Philip Charles Hoffman